Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study.
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
17 11 2022
17 11 2022
Historique:
received:
15
06
2022
accepted:
03
11
2022
entrez:
18
11
2022
pubmed:
19
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
This study aimed to investigate the trajectory of damage accrual, associated factors, and impact on health-related quality of life (HR-QoL) in a multicenter cohort of patients with Behçet's syndrome (BS) over 2 years of follow-up. Patients recruited in the BS Overall Damage Index (BODI) validation study were prospectively monitored for 2 years and assessed for damage accrual, defined as an increase ≥1 in the BODI score, and HR-QoL was evaluated by the SF-36 questionnaire. Logistic and multiple linear regression models were built to determine factors associated with damage accrual and impairment in the different SF-36 domains. During follow-up, 36 out of 189 (19.0%) patients had an increase ≥1 in the BODI score with a mean (SD) difference of 1.7 (0.8) (p <0.001). The incidence rate of damage accrual was stable over time, regardless of the disease duration. Out of 61 new BODI items, 25 (41.0%) were considered related to glucocorticoid (GC) use. In multivariate analysis, duration of GC therapy (OR per 1-year 1.15, 95% CI 1.07-1.23; p <0.001) and occurrence of ≥1 disease relapse (OR 3.15, 95% CI 1.09-9.12; p 0.038) were identified as predictors of damage accrual, whereas the use of immunosuppressants showed a protective effect (OR 0.20, 95% CI 0.08-0.54, p<0.001). Damage accrual was independently associated with the impairment of different physical domains and, to a greater extent, in emotional domains of the SF-36 questionnaire. Female sex, higher disease activity, and fibromyalgia were also significantly associated with impairment in HR-QoL. In BS, organ damage accrues over time, also in long-standing disease, resulting in an impairment of the perceived physical and mental health. Adequate immunosuppressive treatment, preventing disease flares and minimizing exposure to GCs have a crucial role in lowering the risk of damage accrual.
Sections du résumé
BACKGROUND
This study aimed to investigate the trajectory of damage accrual, associated factors, and impact on health-related quality of life (HR-QoL) in a multicenter cohort of patients with Behçet's syndrome (BS) over 2 years of follow-up.
METHODS
Patients recruited in the BS Overall Damage Index (BODI) validation study were prospectively monitored for 2 years and assessed for damage accrual, defined as an increase ≥1 in the BODI score, and HR-QoL was evaluated by the SF-36 questionnaire. Logistic and multiple linear regression models were built to determine factors associated with damage accrual and impairment in the different SF-36 domains.
RESULTS
During follow-up, 36 out of 189 (19.0%) patients had an increase ≥1 in the BODI score with a mean (SD) difference of 1.7 (0.8) (p <0.001). The incidence rate of damage accrual was stable over time, regardless of the disease duration. Out of 61 new BODI items, 25 (41.0%) were considered related to glucocorticoid (GC) use. In multivariate analysis, duration of GC therapy (OR per 1-year 1.15, 95% CI 1.07-1.23; p <0.001) and occurrence of ≥1 disease relapse (OR 3.15, 95% CI 1.09-9.12; p 0.038) were identified as predictors of damage accrual, whereas the use of immunosuppressants showed a protective effect (OR 0.20, 95% CI 0.08-0.54, p<0.001). Damage accrual was independently associated with the impairment of different physical domains and, to a greater extent, in emotional domains of the SF-36 questionnaire. Female sex, higher disease activity, and fibromyalgia were also significantly associated with impairment in HR-QoL.
CONCLUSION
In BS, organ damage accrues over time, also in long-standing disease, resulting in an impairment of the perceived physical and mental health. Adequate immunosuppressive treatment, preventing disease flares and minimizing exposure to GCs have a crucial role in lowering the risk of damage accrual.
Identifiants
pubmed: 36397162
doi: 10.1186/s13075-022-02947-y
pii: 10.1186/s13075-022-02947-y
pmc: PMC9670626
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Informations de copyright
© 2022. The Author(s).
Références
Arthritis Care Res (Hoboken). 2022 Apr;74(4):691-699
pubmed: 33202101
Ann Rheum Dis. 2018 Jun;77(6):808-818
pubmed: 29625968
Rheumatology (Oxford). 2011 Feb;50(2):299-310
pubmed: 21059670
J Rheumatol. 2010 Oct;37(10):2081-5
pubmed: 20682665
Front Med (Lausanne). 2021 Dec 13;8:769870
pubmed: 34966756
Medicine (Baltimore). 2003 Jan;82(1):60-76
pubmed: 12544711
Ann Rheum Dis. 2015 Jan;74(1):177-84
pubmed: 24243925
Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S18-22
pubmed: 19796527
Nat Rev Rheumatol. 2020 Mar;16(3):133-144
pubmed: 32034322
Ann Rheum Dis. 2013 Dec;72(12):1905-13
pubmed: 23873876
Nat Rev Rheumatol. 2018 Feb;14(2):107-119
pubmed: 29296024
Arthritis Res Ther. 2020 Nov 25;22(1):278
pubmed: 33239083
RMD Open. 2020 Jul;6(2):
pubmed: 32703843
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Patient Prefer Adherence. 2015 Nov 13;9:1635-6
pubmed: 26622171
J Rheumatol. 2016 Jun;43(6):1050-6
pubmed: 27084911
Rheumatology (Oxford). 1999 Aug;38(8):728-33
pubmed: 10501420
J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47
pubmed: 23441863